Zacks.com on MSN18h
Merck Halts Second PAH Drug Study Early on Strong Efficacy Results
Merck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension ...
appliedclinicaltrialsonline19h
Kazia Therapeutics Launches Clinical Trial Evaluating Paxalisib in Combination with Keytruda or Lynparza for the Treatment of Advanced Breast Cancer
John Friend, MD, CEO of Kazia Therapeutics added, "The novelty of the science that Professor Rao has proposed with this dual ...
Pulmonaryhypertensionnews.com20h
Early Winrevair trial end to allow all patients to start active treatment
Merck is ending a Phase 3 trial of Winrevair early so all PAH patients in HYPERION can start active treatment with the drug ...
appliedclinicaltrialsonline21h
Bexicaserin Produces Significant Seizure Reduction in PACIFIC OLE Trial for Developmental and Epileptic Encephalopathies
The 12-month open-label extension of the PACIFIC trial demonstrated that bexicaserin significantly reduced seizure frequency ...